Epi One March Update

Mar 4, 2025

Epi One CEO Michael Marquardt provides an update on the latest news on developments in our current laboratory, our search for additional lab space in Delaware, expansion of our research team, and partnerships with medical centers around the country for clinical validation.

 

MORE NEWS

Nemours 2025 Gala Supports Pediatric Cancer Research

Epi One CEO Michael Marquardt recently had the honor of attending the annual gala of the Nemours Children’s ...

Epi One Debuts Early Detection Assay Data at AACR 2025 Annual Meeting

Last week marked a milestone for Epi One: we presented for the first time at the American Association ...

American Cancer Society Medal of Honor Ceremony

Epi One CEO Michael Marquardt had the privilege of attending the American Cancer Society Medal of Honor ceremony ...

Epi One to Present Poster Session at AACR Conference

We are delighted to confirm that we will be presenting a poster session at this year's American Association ...

Epi One Raises $2.1 Million in Successful Equity Crowdfunding Campaign

Epi One, a trailblazer in cancer diagnostics, is thrilled to announce the successful conclusion of its equity crowdfunding ...

Transforming Early Cancer Detection: Latest Webinar Highlights

At Epi One, we're on a mission to revolutionize how cancer is detected and diagnosed. During our recent ...

Join Us for Epi One’s Final Investment Webinar – A Conversation with CEO Michael Marquardt and Chief Scientist & Founder Dr. Fang

As our StartEngine campaign enters its final weeks, we're excited to invite you to a special webinar event ...

Epi One: Top Reasons to Invest Today

7 Reasons to Invest in Epi One: Transforming Cancer Detection Imagine a world where a simple test could ...

Webinar Recap: Transforming Lives Through Early Cancer Detection

At Epi One, we're on a mission to change the landscape of cancer detection. Our recent webinar, led ...

Market Opportunity with Epi One

Market Opportunity with Epi One We believe Epi One is at the vanguard of the rapidly evolving cancer ...
Scroll to Top